{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:58Z","timestamp":1788174598614,"version":"build-2803163510"},"reference-count":28,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeiGene USA, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.2217\/fon-2020-0794","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T09:36:56Z","timestamp":1601285816000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma"],"prefix":"10.1080","volume":"17","author":[{"given":"Martin","family":"Dreyling","sequence":"first","affiliation":[{"name":"LMU University Hospital, \rMunich, \r81377, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S","family":"Tam","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, St Vincent\u2019s Hospital, Royal Melbourne Hospital, University of Melbourne, \rMelbourne, Victoria3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, \rHouston, \rTX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Washington\/Fred Hutchinson Cancer Research Center, \rSeattle, \rWA98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, \rAlessandria, 15121, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, Guangzhou, \rGuangdong Province, \r510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Novotny","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., \rSan Mateo, CA94403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melannie","family":"Co","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., \rSan Mateo, CA94403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Romano","sequence":"additional","affiliation":[{"name":"BeiGene Switzerland GmbH, \r4051Basel, \rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Holmgren","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., \rSan Mateo, CA94403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[{"name":"BeiGene USA, Inc., \rSan Mateo, CA94403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Le","family":"Gouill","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nantes, \r44093Nantes, \rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"issue":"5","key":"e_1_3_4_3_1","first-page":"297","article-title":"Update in the management of mantle cell lymphoma","volume":"11","author":"Goy A","year":"2013","unstructured":"Goy A . Update in the management of mantle cell lymphoma. Clin. Adv. Hematol. Oncol.11(5), 297\u2013299 (2013).","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"1","key":"e_1_3_4_4_1","first-page":"44","article-title":"Mantle cell lymphoma: state of the art","volume":"13","author":"Skarbnik AP","year":"2015","unstructured":"Skarbnik AP , GoyAH. Mantle cell lymphoma: state of the art. Clin. Adv. Hematol. Oncol.13(1), 44\u201355 (2015).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.010"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2202"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"issue":"1","key":"e_1_3_4_8_1","first-page":"4684","article-title":"MCL treatments and outcomes: a community oncology practice experience","volume":"130","author":"Sharman J","year":"2017","unstructured":"Sharman J , BlackShinn J, ClarkJet al. MCL treatments and outcomes: a community oncology practice experience. Blood130(Suppl. 1), 4684 (2017).","journal-title":"Blood"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12573"},{"key":"e_1_3_4_16_1","unstructured":"Imbruvica (ibrutinib) package insert. Pharmacyclics LLC CA USA. (2020)."},{"key":"e_1_3_4_17_1","unstructured":"Calquence (acalabrutinib) package insert. AstraZeneca Pharmaceuticals LP DE USA. (2019)."},{"key":"e_1_3_4_18_1","unstructured":"Brukinsa (zanubrutinib) package insert. BeiGene USA Inc CA USA. (2019)."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.832.832"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.55_2630"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000562920.26603.5b"},{"key":"e_1_3_4_25_1","unstructured":"National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology \u2013 B-cell lymphomas. Version 5. (2018)."},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1804.1804"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:42:20Z","timestamp":1719110540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.2217\/fon-2020-0794"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0794","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}